These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 31960079)

  • 1. Is biological therapy in systemic sclerosis the answer?
    Misra DP; Ahmed S; Agarwal V
    Rheumatol Int; 2020 May; 40(5):679-694. PubMed ID: 31960079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of biologics for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: Information from a Japanese hospital claims database.
    Narita Y; Funatogawa T; Mii K; Adachi H; Tamura A; Yamakido S
    Mod Rheumatol; 2023 Apr; 33(3):525-532. PubMed ID: 35652700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease.
    Ebata S; Yoshizaki A; Fukasawa T; Miura S; Takahashi T; Sumida H; Asano Y; Sato S
    J Dermatol; 2019 Nov; 46(11):1006-1013. PubMed ID: 31502326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in biological and targeted therapies for systemic sclerosis.
    Mulcaire-Jones E; Low AHL; Domsic R; Whitfield ML; Khanna D
    Expert Opin Biol Ther; 2023 Apr; 23(4):325-339. PubMed ID: 36964674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial.
    Khanna D; Lin CJF; Furst DE; Wagner B; Zucchetto M; Raghu G; Martinez FJ; Goldin J; Siegel J; Denton CP
    Am J Respir Crit Care Med; 2022 Mar; 205(6):674-684. PubMed ID: 34851799
    [No Abstract]   [Full Text] [Related]  

  • 6. Relevance of immunomodulatory therapy for interstitial lung disease in systemic sclerosis.
    Aringer M; Riemekasten G
    Best Pract Res Clin Rheumatol; 2021 Sep; 35(3):101672. PubMed ID: 33745826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment Algorithms for Systemic Sclerosis According to Experts.
    Fernández-Codina A; Walker KM; Pope JE;
    Arthritis Rheumatol; 2018 Nov; 70(11):1820-1828. PubMed ID: 29781586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial.
    Saunders P; Tsipouri V; Keir GJ; Ashby D; Flather MD; Parfrey H; Babalis D; Renzoni EA; Denton CP; Wells AU; Maher TM
    Trials; 2017 Jun; 18(1):275. PubMed ID: 28619061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment with rituximab in a Japanese patient with systemic sclerosis-associated interstitial lung disease resistant to oral steroid and cyclophosphamide.
    Numajiri H; Yoshizaki A; Ebata S; Fukasawa T; Yamashita T; Takahashi T; Taniguchi T; Asano Y; Sato S
    J Dermatol; 2018 Jun; 45(6):e140-e141. PubMed ID: 29265579
    [No Abstract]   [Full Text] [Related]  

  • 10. A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease.
    Daoussis D; Melissaropoulos K; Sakellaropoulos G; Antonopoulos I; Markatseli TE; Simopoulou T; Georgiou P; Andonopoulos AP; Drosos AA; Sakkas L; Liossis SN
    Semin Arthritis Rheum; 2017 Apr; 46(5):625-631. PubMed ID: 27839742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2023 Brazilian Society of Rheumatology guidelines for the treatment of systemic sclerosis.
    Kayser C; de Oliveira Delgado SM; Zimmermann AF; Horimoto AMC; Del Rio APT; de Souza Müller C; Camargo CZ; Lupo CM; de Moraes DA; Do Rosário E Souza EJ; Santos FPST; Sekiyama JY; Lonzetti LS; de Oliveira Martins LV; Bezerra MC; Bredemeier M; Oliveira MC; da Fonseca Salgado MC; Miossi R; de Araújo Fontenele SM; Hax V; Dantas AT; Sampaio-Barros PD
    Adv Rheumatol; 2024 Jul; 64(1):52. PubMed ID: 38987832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies.
    Lescoat A; Roofeh D; Kuwana M; Lafyatis R; Allanore Y; Khanna D
    Clin Rev Allergy Immunol; 2023 Jun; 64(3):239-261. PubMed ID: 34468946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy with rituximab and mycophenolate mofetil in systemic sclerosis. A single-centre case series study.
    Fraticelli P; Fischetti C; Salaffi F; Carotti M; Mattioli M; Pomponio G; Gabrielli A
    Clin Exp Rheumatol; 2018; 36 Suppl 113(4):142-145. PubMed ID: 30277864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current advances in the treatment of systemic sclerosis.
    Bukiri H; Volkmann ER
    Curr Opin Pharmacol; 2022 Jun; 64():102211. PubMed ID: 35447517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature.
    Giuggioli D; Lumetti F; Colaci M; Fallahi P; Antonelli A; Ferri C
    Autoimmun Rev; 2015 Nov; 14(11):1072-8. PubMed ID: 26209905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STRATUS: A Phase II Study of Abituzumab in Patients With Systemic Sclerosis-associated Interstitial Lung Disease.
    Khanna D; Tashkin DP; Wells AU; Seibold JR; Wax S; Vazquez-Mateo C; Fleuranceau-Morel P; Damian D; Denton CP
    J Rheumatol; 2021 Aug; 48(8):1295-1298. PubMed ID: 33004536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor α agents, a retrospective cohort study.
    Curtis JR; Sarsour K; Napalkov P; Costa LA; Schulman KL
    Arthritis Res Ther; 2015 Nov; 17():319. PubMed ID: 26555431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of tocilizumab in Japanese patients with systemic sclerosis and associated interstitial lung disease: A subgroup analysis of a global, randomised, controlled Phase 3 trial.
    Kuwana M; Takehara K; Tanaka Y; Yamashita K; Katsumata K; Takata M; Shima Y
    Mod Rheumatol; 2024 Mar; 34(3):530-540. PubMed ID: 37436828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current and future perspectives on management of systemic sclerosis-associated interstitial lung disease.
    Distler O; Volkmann ER; Hoffmann-Vold AM; Maher TM
    Expert Rev Clin Immunol; 2019 Oct; 15(10):1009-1017. PubMed ID: 31566449
    [No Abstract]   [Full Text] [Related]  

  • 20. [New developments in systemic sclerosis-associated interstitial lung disease].
    Humair G; Daccord C; Beigelman-Aubry C; Lazor R
    Rev Med Suisse; 2020 Nov; 16(715):2218-2223. PubMed ID: 33206479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.